Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan

被引：0
|
作者：
Yasuo Yanagi
Kanji Takahashi
Tomohiro Iida
Fumi Gomi
Junko Morii
Eriko Kunikane
Taiji Sakamoto
机构：
[1] Yokohama City University,Department of Ophthalmology and Microtechnology
[2] Kansai Medical University,Department of Ophthalmology
[3] Tokyo Women’s Medical University School of Medicine,Department of Ophthalmology
[4] Hyogo Medical University,Department of Ophthalmology
[5] IQVIA Solutions Japan,Department of Ophthalmology
[6] K.K.,undefined
[7] Senju Pharmaceutical Co.,undefined
[8] Ltd.,undefined
[9] Kagoshima University Graduate School of Medical and Dental Sciences,undefined
来源：
Ophthalmology and Therapy | 2023年 / 12卷
关键词：
Cost-effectiveness; Costs and cost analysis; Dosing regimens; Japan; Markov model; Neovascular age-related macular degeneration; Ranibizumab biosimilar; Societal perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2005 / 2021
页数：16
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
    Yanagi, Yasuo
    Takahashi, Kanji
    Iida, Tomohiro
    Gomi, Fumi
    Morii, Junko
    Kunikane, Eriko
    Sakamoto, Taiji
    OPHTHALMOLOGY AND THERAPY, 2023, 12 (04) : 2005 - 2021
  • [2] Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
    Yasuo Yanagi
    Kanji Takahashi
    Tomohiro Iida
    Fumi Gomi
    Junko Morii
    Eriko Kunikane
    Taiji Sakamoto
    Ophthalmology and Therapy, 2023, 12 : 2821 - 2822
  • [3] Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
    Hurley S.F.
    Matthews J.P.
    Guymer R.H.
    Cost Effectiveness and Resource Allocation, 6 (1)
  • [4] Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan (vol 12, pg 2005, 2023)
    Yanagi, Yasuo
    Takahashi, Kanji
    Iida, Tomohiro
    Gomi, Fumi
    Morii, Junko
    Kunikane, Eriko
    Sakamoto, Taiji
    OPHTHALMOLOGY AND THERAPY, 2023, 12 (05) : 2821 - 2822
  • [5] Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan
    Yanagi, Yasuo
    Takahashi, Kanji
    Iida, Tomohiro
    Gomi, Fumi
    Onishi, Hiroshi
    Morii, Junko
    Sakamoto, Taiji
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (10) : 2629 - 2644
  • [6] Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
    Luis Javier Hernández-Pastor
    Ana Ortega
    Alfredo García-Layana
    Joaquín Giráldez
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248 : 467 - 476
  • [7] Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
    Javier Hernandez-Pastor, Luis
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (04) : 467 - 476
  • [8] Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
    Yu, Justin S.
    Carlton, Rashad
    Agashivala, Neetu
    Hassan, Tarek
    Wykoff, Charles C.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (06): : 743 - 752
  • [9] Cost-Effectiveness of Ranibizumab Compared with Photodynamic Treatment of Neovascular Age-Related Macular Degeneration
    Javier Hernandez-Pastor, Luis
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    CLINICAL THERAPEUTICS, 2008, 30 (12) : 2436 - 2451
  • [10] Cost-effectiveness of ranibizumab and bevacizumab for neovascular age-related macular degeneration: 1 year IVAN results
    Rogers, Chris
    Dakin, Helen
    Wordsworth, Sarah
    Abangma, Giselle
    Raftery, James
    Harding, Simon
    Chakravarthy, Usha
    Lotery, Andrew
    Downes, Susan
    Reeves, Barnaby
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
12345